Cantor Fitzgerald reaffirmed their hold rating on shares of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) in a research note published on Thursday. The firm currently has a $3.00 price target on the biopharmaceutical company’s stock.

“Advancing Toward SNS-062 Data. SNSS has just begun enrolling patients in a Phase Ib study for SNS-062, which could have utility in ibrutinib-treated patients that develop a common resistance mutation (C481) and exploring the compound in CLL and other B-cell malignancies. Results from escalation cohorts could occur in 2Q18 (possibly ASCO, AACR), which could present a revaluation opportunity for the shares.”,” Cantor Fitzgerald’s analyst commented.

Separately, Zacks Investment Research raised shares of Sunesis Pharmaceuticals from a hold rating to a buy rating and set a $3.50 price objective for the company in a research note on Thursday, May 11th.

Sunesis Pharmaceuticals (SNSS) traded up 2.896% on Thursday, reaching $2.665. The company’s stock had a trading volume of 24,160 shares. The stock’s market capitalization is $62.66 million. Sunesis Pharmaceuticals has a 52 week low of $2.47 and a 52 week high of $6.30. The firm has a 50 day moving average price of $2.75 and a 200 day moving average price of $3.53.

Sunesis Pharmaceuticals (NASDAQ:SNSS) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.76) by $0.35. During the same quarter in the previous year, the firm earned ($0.12) EPS. On average, equities analysts anticipate that Sunesis Pharmaceuticals will post ($2.02) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This story was first reported by Watch List News and is owned by of Watch List News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at https://www.watchlistnews.com/sunesis-pharmaceuticals-inc-nasdaqsnss-rating-reiterated-by-cantor-fitzgerald/1463709.html.

Institutional investors have recently bought and sold shares of the stock. Renaissance Technologies LLC raised its position in Sunesis Pharmaceuticals by 1.1% in the first quarter. Renaissance Technologies LLC now owns 111,811 shares of the biopharmaceutical company’s stock valued at $458,000 after buying an additional 1,230 shares during the last quarter. Neuberger Berman Group LLC raised its position in Sunesis Pharmaceuticals by 16.6% in the first quarter. Neuberger Berman Group LLC now owns 140,555 shares of the biopharmaceutical company’s stock valued at $576,000 after buying an additional 20,000 shares during the last quarter. Finally, TFS Capital LLC acquired a new position in Sunesis Pharmaceuticals during the first quarter valued at $158,000. Institutional investors and hedge funds own 55.15% of the company’s stock.

Sunesis Pharmaceuticals Company Profile

Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).

Receive News & Ratings for Sunesis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.